Dimitris Voliotis - 18 Jan 2022 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role: SVP, Clinical Development
Signature: /s/ Melissa B. Epperly, Attorney-in-Fact for Dimitris Voliotis
Issuer symbol: ZNTL
Transactions as of: 18 Jan 2022
Net transactions value: -$1,300,745
Form type: 4
Filing time: 20 Jan 2022, 18:15:07 UTC
Next filing: 14 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ZNTL	Common Stock	Options Exercise	$180,000	+10,000	+160%	$18.00	16,250	18 Jan 2022	Direct	F1
transaction	ZNTL	Common Stock	Sale	$210,326	-3,409	-21%	$61.70	12,841	18 Jan 2022	Direct	F1, F2
transaction	ZNTL	Common Stock	Sale	$205,334	-3,294	-26%	$62.34	9,547	18 Jan 2022	Direct	F1, F3
transaction	ZNTL	Common Stock	Sale	$126,767	-1,997	-21%	$63.48	7,550	18 Jan 2022	Direct	F1, F4
transaction	ZNTL	Common Stock	Sale	$84,064	-1,300	-17%	$64.66	6,250	18 Jan 2022	Direct	F1, F5
transaction	ZNTL	Common Stock	Options Exercise	$180,000	+10,000	+160%	$18.00	16,250	19 Jan 2022	Direct	F1
transaction	ZNTL	Common Stock	Sale	$477,683	-7,889	-49%	$60.55	8,361	19 Jan 2022	Direct	F1, F6
transaction	ZNTL	Common Stock	Sale	$95,707	-1,556	-19%	$61.51	6,805	19 Jan 2022	Direct	F1, F7
transaction	ZNTL	Common Stock	Sale	$34,541	-555	-8.2%	$62.24	6,250	19 Jan 2022	Direct	F1, F8
transaction	ZNTL	Common Stock	Options Exercise	$180,000	+10,000	+160%	$18.00	16,250	20 Jan 2022	Direct	F1
transaction	ZNTL	Common Stock	Sale	$504,904	-8,343	-51%	$60.52	7,907	20 Jan 2022	Direct	F1, F9
transaction	ZNTL	Common Stock	Sale	$101,419	-1,657	-21%	$61.21	6,250	20 Jan 2022	Direct	F1, F10

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ZNTL	Stock Option	Options Exercise	$0	-10,000	-6.5%	$0.000000	144,949	18 Jan 2022	Common Stock	10,000	$18.00	Direct	F1, F11
transaction	ZNTL	Stock Option	Options Exercise	$0	-10,000	-6.9%	$0.000000	134,949	19 Jan 2022	Common Stock	10,000	$18.00	Direct	F1, F11
transaction	ZNTL	Stock Option	Options Exercise	$0	-10,000	-7.4%	$0.000000	124,949	20 Jan 2022	Common Stock	10,000	$18.00	Direct	F1, F11

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2021.
F2	The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $60.97 to $61.96. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3	The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $61.98 to $62.93. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4	The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $63.18 to $64.02. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5	The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $64.23 to $65.19. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6	The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $60.07 to $61.05. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7	The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $61.09 to $61.94. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8	The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $62.15 to $62.41. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F9	The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $60.00 to $60.95. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F10	The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $61.01 to $61.61. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11	The option vests and becomes exercisable as to 25% of the shares on March 25, 2021 and vests in equal monthly installments thereafter until March 25, 2024.